Picture of Maze Therapeutics logo

MAZE Maze Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapContrarian

Momentum

Relative Strength (%)
1m-0.71%
3m-28.29%
6mn/a
1yrn/a
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-36.18%
50d MA+5.14%
200d MA-0.47%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital26.19%
Return on Equity3.29%
Operating Margin34.38%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202531st Dec 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of Maze Therapeutics EPS forecast chart

Profile Summary

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.

Directors

    Last Annual
    December 31st, 2024
    Last Interim
    December 31st, 2024
    Incorporated
    August 29th, 2017
    Public Since
    January 31st, 2025
    No. of Shareholders
    210
    No. of Employees
    125
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Global Market
    Shares in Issue
    43,796,057

    MAZE Share Price Performance

    Upcoming Events for MAZE

    Similar to MAZE

    Picture of 89bio logo

    89bio

    us flag iconNASDAQ Global Market

    Picture of Abivax SA logo

    Abivax SA

    us flag iconNASDAQ Global Market

    Picture of ABPRO Holdings logo

    ABPRO Holdings

    us flag iconNASDAQ Global Market

    Picture of AC Immune SA logo

    AC Immune SA

    us flag iconNASDAQ Global Market

    Picture of Acrivon Therapeutics logo

    Acrivon Therapeutics

    us flag iconNASDAQ Global Market

    FAQ